After adjustment for fundamental covariates in Model 1, per SD increment of serum albumin was associated with a lower risk of incident MS (HR=0.94, 95% CI: 0.91–0.98, P=7.66E-04) (Figure 2A). Here, ALB is linked to myeloid sarcoma.